NEWS RELEASE
nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) is pleased to review its advanced mental condition diagnostic system.
Calgary, Alberta – February 20, 2024
For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) ) ) is pleased to review its advanced mental condition diagnostic system that promises to fundamentally change mental health diagnosis, management and treatment.
INTRODUCTION
nDatalyze Corp. (“NDAT”) is at the forefront of AI/ML-based (ML) mental health diagnostics through its YMI Clinical Decision Support System. YMI is currently operational and undergoing validation by an elite team of researchers and clinical experts through two Clinical Studies. Leveraging proprietary databases and algorithms, YMI addresses the critical challenge of misdiagnosis in mental health.
James Durward, CEO, states: “Our purpose-built and proprietary databases are what really set us apart from others in this sector. While high quality ML algorithms are abundant, without relevant, consistent, clean data to feed the ML algorithms, you can’t get quality results. Perhaps an even bigger issue is copyright – while others must deal with potential copyright infringement claims related to the training data they use, we have full rights to our data. We recognized the value of high quality data from the get-go and I believe that this is a major differentiator that positions NDAT as a transformative player in the sector.”
KEY PERSONNEL AND COLLABORATIONS
At the helm of nDatalyze Corp. is CEO Jim Durward, a visionary data scientist pivotal to the company’s pioneering approach in mental health diagnostics. The team is further strengthened by NDAT’s President, Dr. Keith Courtney, PhD, Psychiatrist.
Significantly contributing to the clinical research are distinguished academics Dr. Andrew Greenshaw, PhD, Professor of Psychiatry and Neuroscience at the University of Alberta, and Dr. Bo Cao, PhD, Canada Research Chair in Computational Psychiatry. Their expertise is instrumental in one Clinical Study, being conducted under the auspices of the Canadian Mental Health Association (CMHA).
Another key collaboration involves Dr. Dale Stevens, Neuroscience PhD, from the Department of Psychology at York University. Dr. Stevens is leading a Clinical Study related to the incorporation of DNA data into the predictive algorithm. The DNA-enhanced data collection was completed in January, 2024 and these records form part of NDAT’s purpose-built databases.
These collaborations underscore NDAT’s commitment to ensuring its technologies meet the highest standards of efficacy and ethical practice, both critical factors for investor confidence.
INNOVATIVE APPROACH AND MARKET POSITIONING
NDAT’s collaborative approach does more than just advance the field of mental health; it positions NDAT as a leader in a vast and growing market. By focusing on combining predictive diagnostics, condition management and treatment, NDAT taps into an unmet need in the mental health sector, offering a solution that can potentially transform how mental conditions are diagnosed, managed and treated. This innovative stance not only underscores NDAT’s technological prowess but also highlights its potential for significant market growth and impact.
REGULATORY EXCELLENCE AND PATIENT SAFETY
In its unwavering pursuit of excellence, nDatalyze Corp. (NDAT) places a strong emphasis on regulatory compliance and ethical standards. NDAT conducts extensive ethics reviews in collaboration with its academic partners, ensuring full adherence to applicable regulations. This strict compliance not only demonstrates NDAT’s commitment to patient safety but also underlines its dedication to sustainable growth in the mental health sector. By prioritizing these aspects, NDAT aligns itself with the highest standards of practice, reinforcing investor confidence in the company’s operational integrity and long-term viability. This approach is particularly crucial in the healthcare industry, where regulatory compliance and patient safety are paramount.
CAPITAL
NDAT has sufficient funds on hand to fund both Clinical Studies. NDAT has no debt.
ENGAGEMENT AND INVITATION TO INVESTORS
nDatalyze Corp. cordially invites the investment community to explore the unique and innovative approach we have adopted towards mental health care. We are eager to engage in further discussions about our strategic direction and the exciting investment opportunities that lie ahead.
Dr. Keith Courtney, President (psychiatric aspects)
Email: [email protected]
James Durward, CEO&CTO (technical aspects)
Telephone: (403) 689-3901
Email: [email protected]
Website: www.ndatalyze.com
YMI Website: https://ymihealth.ca
ABOUT YMI
YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time, and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual’s predisposition toward a variety of common mental conditions, both current and forward in time.
nDatalyze’s YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns both societal impact and financial success.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.